Long term azithromycin therapy in patients with cystic fibrosis

Creative Commons License

EMİRALİOĞLU N., Öztürk Z., Yalçın E., Doğru D., Özçelik U., Kiper N.

TURKISH JOURNAL OF PEDIATRICS, vol.58, no.1, pp.34-40, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 58 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.24953/turkjped.2016.01.005
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.34-40
  • Keywords: cystic fibrosis, inflammation, macrolide, lung function, nutrition, PSEUDOMONAS-AERUGINOSA, MAINTENANCE, MACROLIDES
  • Hacettepe University Affiliated: Yes


Inflammation is a central contributor to the pathogenesis of cystic fibrosis (CF) pulmonary disease; so limiting the excessive production of inflammatory mediators represents a major therapeutic strategy for slowing the decline in lung function and improving survival. The macrolide antibiotic azithromycin (AZM) has anti-inflammatory properties and immunomodulatory effects that may be beneficial in CF. The aim of this study was to document the long term use of AZM effect on pulmonary function, nutritional status and number of pulmonary exacerbations in patients with CF.